Novartis is intending to hand back rights to Aveo Oncology’s experimental antibody AV-380, which it acquired in August 2015 in a deal valued at at least $326 million.
The antibody targets GDF15, a pro-inflammatory cytokine elevated levels of which have been correlated with cachexia - a complex metabolic syndrome linked with malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue - in patients with cancer and other conditions.
Read more : http://www.pharmatimes.com/news/novartis_to_hands_back_rights_to_aveos_av-380_1243124